These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12163888)

  • 1. [Tolerability, safety and efficacy of Iloprost infusion without peristaltic pump in systemic sclerosis].
    Arreghini M; Prudente P; Maglione W; Arnoldi C; Tosi S; Marchesoni A
    Reumatismo; 2001; 53(2):140-144. PubMed ID: 12163888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.
    Bixio R; Adami G; Bertoldo E; Giollo A; Morciano A; Bertelle D; Orsolini G; Idolazzi L; Rossini M; Viapiana O
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221137125. PubMed ID: 36439640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and persistence of intravenous iloprost in systemic sclerosis.
    Martins P; Dourado E; Fonseca JE; Romão V; Resende C
    ARP Rheumatol; 2022; 1(2):122-128. PubMed ID: 35810370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
    Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
    Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases].
    García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J
    Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of iloprost in systemic sclerosis in a real-life experience.
    Bellando-Randone S; Bruni C; Lepri G; Fiori G; Bartoli F; Conforti ML; Moggi-Pignone A; Guiducci S; Giuggioli D; Colaci M; Spinella A; Ferri C; Matucci-Cerinic M
    Clin Rheumatol; 2018 May; 37(5):1249-1255. PubMed ID: 29470737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study.
    Colaci M; Lumetti F; Giuggioli D; Guiducci S; Bellando-Randone S; Fiori G; Matucci-Cerinic M; Ferri C
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):179-183. PubMed ID: 28980901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Janssena MC; Wollersheim H; Kraus C; Hildebrand M; Watson HR; Thien T
    Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloprost infusion through elastomeric pump in the treatment of Raynaud's phenomenon and digital ulcers.
    Fartura Braga Temido MH; Gomes M; Parente F; Santos L
    J Scleroderma Relat Disord; 2019 Feb; 4(1):NP1-NP4. PubMed ID: 35382145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
    Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.